melphalan (Alkeran, L-PAM, L-sarcolysin phenylalanine mustard, melphalan flufenamide, Pepaxto)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Alkeran.

Indications

Contraindications

  • melphalan flufenamide (Pepaxto) does not improve progression-free or overall survival; may lose FDA accelerated approval granted in Feb 2021[5]

Dosage

  • 0.25 mg/kg/day PO for 4 days every 6 weeks
  • maximum: 6 mg/day

Tabs: 2 mg (preferred route of administration is oral)

Powder for injection: 50 mg (10 mL)

Do:

  • protect from light
  • do not refrigerate reconstituted solution
  • complete administration within 1 hour of reconstitution

Pharmacokinetics

elimination via plasma

1/2life = 1.5-4 hours

Adverse effects

Drug interactions

Test interactions

Mechanism of action

More general terms

Component of

References

  1. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  2. 2.0 2.1 Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  3. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 529
  4. 4.0 4.1 4.2 Deprecated Reference
  5. 5.0 5.1 Young KD Follow-up Trial of Myeloma Drug 'Flopped,' Says FDA Panel. Medscape. September 23, 2022 https://www.medscape.com/viewarticle/981343

Database